Diabetes Drug Gliclazide Boosts Exercise Performance by 23% in Healthy Athletes

This groundbreaking study reveals how a common diabetes medication might enhance athletic performance, though with significant safety concerns that limit its practical application for healthy individuals.

Researchers conducted a rigorous double-blind, placebo-controlled crossover trial with 44 strength-trained men. Participants received either 90mg of gliclazide modified-release or placebo 8 hours before three consecutive strength training sessions involving bench press and squat exercises at 80% of their one-repetition maximum.

The results were striking: gliclazide enhanced total training volume by 23.3% for bench press and 23.2% for squat exercises compared to placebo. Recovery metrics showed equally impressive improvements, including 13.2% reduction in muscle damage markers, 17.4% decrease in inflammatory proteins, 17.7% less muscle soreness, and 32.5% better recovery scores. Range of motion also improved significantly.

For longevity and health optimization, enhanced exercise performance and faster recovery could theoretically support better training adaptations, muscle preservation, and metabolic health. However, the critical safety concern emerged when 7% of participants experienced hypoglycemic episodes—dangerously low blood sugar levels that can cause serious health complications.

This research primarily serves as proof-of-concept for understanding exercise physiology rather than a practical intervention. The hypoglycemia risk makes gliclazide unsuitable for performance enhancement in healthy individuals. The findings may inform future development of safer compounds that could provide similar benefits without glucose-related side effects, potentially benefiting both athletic performance and healthy aging through improved exercise capacity.